With immense of optimism and confidence, we have agreed to perform a multi-national clinical evaluation for the assessment of our first product, the miniMDR-TB® test. The product will be validated in at least seven WHO sponsored Supernational Reference Laboratories in Europe and Asia. The clinical evaluation is scheduled to start in Jan. 2017.
EMPE is excited to announce that we have established clinical consortium with premier TBnet for the clinical evaluation of their products.
It is our pleasure to announce that EMPE has received a collaborative research grant to develop a new RCA-ADT rapid detection platform for diarrhoeagenic E. coli and Vibrio Cholerae. The consortium includes University of Loughborough (UK), University of Cambridge (UK), International Centre for Diarrhoeal Disease Research (Bangladesh) and Stockholm University (Sweden).
We are happy to announce the employment of Mr. Jeanpierre Salas, a Biotechnical Engineer from the famous Royal Institute of Technology. Jeanpierre will work on the technical aspects of assay integration and lateral-flow cassette assembling dynamics. Welcome Jeanpierre!
EMPE is very happy to announce about their whole-new lateral flow production and R&D facility. EMPE’s full-range of customized instruments are capable of producing about 5000 lateral flow or dipstick tests in one hour, which makes us unique for Sweden.